Celampa M 12.5/500mg Tablet

Celampa M 12.5/500mg Tablet is a combination medication containing two active ingredients, Empagliflozin & Metformin. It is prescribed for the management of type 2 diabetes mellitus to help control blood sugar levels.

Key Ingredients:

1. Empagliflozin: Empagliflozin belongs to a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It works by inhibiting the reabsorption of glucose in the kidneys, thereby promoting the excretion of excess glucose in the urine. This helps lower blood sugar levels and improve glycemic control.
2. Metformin: Metformin is a biguanide antidiabetic medication that works by reducing the production of glucose in the liver and improving insulin sensitivity in peripheral tissues. It also helps decrease the absorption of glucose from the gastrointestinal tract, leading to lower blood sugar levels.

Uses:

1. Type 2 Diabetes Management: Celampa M 12.5/500mg Tablet is used to treat type 2 diabetes mellitus in adults. It helps lower blood sugar levels by multiple mechanisms, including reducing glucose production by the liver, increasing glucose uptake by peripheral tissues, and promoting the excretion of glucose in the urine.

Administration:

1. Celampa M 12.5/500mg Tablet is typically taken orally, with or without food, as directed by a healthcare professional.
2. The dosage and frequency of administration may vary depending on individual patient characteristics, including the severity of diabetes, renal function, and response to treatment. It is important to follow the prescribed regimen provided by a healthcare provider.
3. Swallow the tablet whole with a glass of water; avoid crushing or chewing it unless advised otherwise.

Precautions:

1. Before using Celampa M 12.5/500mg Tablet, inform your healthcare provider about any allergies, medical conditions, or medications you are taking, especially other antidiabetic medications or drugs that may affect renal function.
2. Monitoring of renal function and electrolyte levels is recommended during treatment with SGLT2 inhibitors such as empagliflozin, as these medications can increase the risk of kidney-related adverse effects, including acute kidney injury and hyperkalemia.
3. Hypoglycemia (low blood sugar) may occur when Celampa M 12.5/500mg Tablet is used in combination with insulin or insulin secretagogues. Patients should be educated about the signs and symptoms of hypoglycemia and how to manage it appropriately.

In Conclusion:

Celampa M 12.5/500mg Tablet, containing Empagliflozin and Metformin, is a combination therapy used for the management of type 2 diabetes mellitus. By targeting multiple pathways involved in glucose metabolism, Celampa M helps improve glycemic control and reduce the risk of diabetes-related complications.